Powerful Drug Combo Gangs Up to Tackle Triple-Negative Breast Cancer

Researchers have found that a novel drug combination disrupts multiple factors in an aggressive type of breast cancer.

7:00 AM

Author | Nicole Fawcett

In the hunt for novel treatments against an aggressive form of breast cancer, University of Michigan researchers recently combined a new protein inhibitor with a chemotherapy drug.

The result: a powerful combination that led to cancer cell death.

MORE FROM THE LAB: Sign up for our weekly newsletter

Triple-negative breast cancer is a subtype that does not express hormone receptor, or HER2. It occurs in about 15 percent of patients with breast cancer. This subtype tends to be more aggressive, and targeted therapeutic treatment options are lacking.

In this work, the drugs were tested separately in triple-negative breast cancer cell lines and in mice with the disease. Researchers then implemented the treatments together.

That combination, they found, produced a synergistic effect that was more effective than either drug alone: Cancer cells treated with the drug combination were less likely to multiply or spread in cell culture and were less viable in an animal model.

Past discoveries drove the pairing.

Preliminary data had shown that inhibiting proteins called cyclin-dependent kinases, or CDKs, might be effective against triple-negative breast cancer. In this study, published in Oncotarget, researchers tested a pharmaceutical-grade CDK inhibitor called CYC065.

Additionally, they used the chemotherapy drug eribulin, which had shown promise in prior clinical trials for the treatment of triple-negative breast cancer.

"In this pre-clinical study, we showed that the combination of CYC065 and eribulin had a synergistic effect against the growth and progression of triple-negative breast cancer," says study author Jacqueline S. Jeruss, M.D., Ph.D., director of the Breast Care Center at the University of Michigan Rogel Cancer Center. "New therapeutic targets and treatment strategies are crucial to improve outcomes for women with this aggressive breast cancer subtype."

A longtime endeavor

From the early days of her career, Jeruss was interested in how signaling pathway alterations could affect the development of breast cancer.

What makes a mammary cell change to allow for lactation but then regress when that function is no longer needed? What orchestrates cell regulation to allow for such carefully mediated physiologic changes?

SEE ALSO: Gaming Cells to Turn Off the Metastases Switch in Breast Cancer

And, perhaps most crucial, what processes occur over time that cause the cellular deregulation leading to cancer development in certain patients but not in others?

Her work led her to the implementation of CDK inhibitors for the treatment of triple-negative breast cancer. Jeruss found that these drugs could help block the harmful impact of overexpression of cyclin E/CDKs cancer-promoting proteins that were inhibiting the tumor-suppressant action of the TGF-beta/SMAD3 pathway. CDK inhibitors, then, can facilitate cancer cell death.

The current study affirms this. The combination of CYC065 with eribulin resulted in less-viable triple-negative breast cancer cells, smaller tumor colonies, decreased cell migration and small tumor size in an animal model.

U-M researchers also identified transcription factors that were affected by CYC065. These processes probably work together to promote cancer cell death.

"We have begun to identify a network of vulnerable and targetable signaling components within the triple-negative cancer cells that can be exploited with CDK inhibitor and chemotherapy treatment to promote triple-negative breast cancer cell death," Jeruss says.

The next step, she adds, is for researchers to develop a clinical trial to test the drug combination in patients with triple-negative breast cancer.

Learn more about breast cancer and breast cancer treatment at the U-M Rogel Cancer Center


More Articles About: Lab Report Breast cancer Drug Discovery Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Spilled pills next to a stethoscope and pile of cash
Health Lab
Drug pricing program improved prostate cancer treatment adherence
Socially vulnerable patients were more likely to stick with oral medications when treated at a hospital participating in 340B program, suggesting these hospitals may have more resources to help patients.
cancer cell blue yellow
Health Lab
Less chemoradiation is possible for some cancer patients
Some oropharynx cancer patients may qualify for less radiation treatments, according to a new study from experts at the University of Michigan Health Rogel Cancer Center.
Animated microscopic image of the glioblastoma's tumor microenvironment
Health Lab
New model of key brain tumor feature could help scientists understand how to develop new treatments
Model shows how oncostreams form and behave in brain tumors – and how to inhibit them
cancer cell blue yellow
Health Lab
Targeted drug shows promising ability in treating rare head and neck cancers
Experts at Rogel Cancer Center develop and study the impact of a new drug for salivary gland cancers
Health care provider with stethoscope holds patient's hand
Health Lab
Combatting prostate cancer stigma
Prostate cancer is highly treatable and over 98% of men survive 10 years if the cancer is diagnosed and treated early.
Don Reynolds, seated at right, and his family gather together. Reynolds can garden with his grandchildren after a successful treatment with Pluvicto. Photos courtesy of the Reynolds family
Health Lab
Pluvicto treatment gives patient another chance
New treatment for metastatic castration resistant prostate cancer helped patient get back to his hobbies